Compare Neurocrine Biosciences Inc (NBIX) vs Truist Financial Corporation Common Stock (TFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Truist Financial Corporation Common Stock — how do they compare? Neurocrine Biosciences Inc trades at $142.45 (market cap $14.36B), while Truist Financial Corporation Common Stock trades at $45.98 (market cap $56.41B). The key difference: Truist Financial Corporation Common Stock is far larger — about 3.9× Neurocrine Biosciences Inc's market cap, and Truist Financial Corporation Common Stock pays a 4.5% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Truist Financial Corporation Common Stock for 0 Days on average.
| NBIX | TFC | |
|---|---|---|
Market Cap | $14.36B | $56.41B |
Volume | 1,237,180 | 9,045,741 |
Sector | Health | Financials |
52-Week High | $185.50 | $55.81 |
52-Week Low | $123.10 | $41.09 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $14.37B | $122.69B |
Dividend Yield | — | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Truist Financial Corporation Common Stock
Truist Financial provides consumer and commercial banking, wealth management, insurance, and investment services in the United States.
Read more on TFC →
